Merck & Co. Stock Performance
Merck & Co. shares closed at $141.98, declining 2.49% in the most recent session, per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum over longer timeframes, gaining 20.43% over the trailing three months and 36.64% over the past twelve months, according to Massive/Polygon data. The stock currently trades below its 50-day moving average of $143.76, suggesting near-term softness, while remaining well above its 200-day moving average of $125.55, which confirms the longer-term uptrend. The 14-day RSI reads 37.7, placing Merck in the lower range and approaching oversold territory. Average daily trading volume stands at approximately 13.4 million shares. The company's beta of 0.299 indicates significantly lower volatility relative to the broader market, consistent with its positioning in the defensive healthcare sector. Merck's market capitalization currently stands at approximately $248.8 billion.
Merck & Co. Valuation Analysis
Merck & Co. trades at a price-to-earnings ratio of 12.99, which positions the company at a discount relative to the broader S&P 500 and many large-cap healthcare peers, per SID market data. The PEG ratio of 0.79 falls below the commonly referenced fair-value threshold of 1.0, suggesting the stock's earnings growth rate may not be fully reflected in the current share price, according to SEC filings. The price-to-book ratio stands at 4.77, a level typical for pharmaceutical companies with substantial intangible assets including drug patents and pipeline intellectual property. Merck offers a dividend yield of 3.27%, providing meaningful income to shareholders and reinforcing the stock's appeal as a defensive holding. Taken together, these valuation metrics indicate Merck is trading at relatively modest multiples compared to its sector, with the sub-1.0 PEG ratio and above-average dividend yield standing out as notable data points for fundamental analysis.
Smart Money Activity for MRK
Merck & Co. registers a smart money composite score of 54 out of 100, reflecting a neutral overall signal, per SID market data. The institutional sub-score is a perfect 25 out of 25, indicating extremely strong institutional ownership and conviction among large fund managers, according to 13F institutional filings. In contrast, the dark pool activity sub-score is notably low at 5.0 out of 25, suggesting limited off-exchange block trading activity in recent periods. The insider trading sub-score stands at 12.0 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days — comprised of 5 purchases and 15 sales. The three-to-one sell-to-buy ratio among insiders warrants monitoring, though insider sales often reflect routine compensation-related liquidations rather than directional conviction. The congressional trading sub-score sits at 12.3 out of 25, reflecting moderate activity among congressional members. The divergence between peak institutional interest and muted dark pool activity creates a mixed smart money picture for Merck.
Merck & Co. Earnings Outlook
Merck & Co.'s most recent reported quarter showed a loss of $1.28 per share, which nonetheless exceeded analyst estimates of a loss of $1.48 per share, representing a positive surprise of $0.20, according to company earnings reports. The subsequent quarter reported a loss of $0.13 per share against an estimate of $0.23 in earnings, reflecting a negative surprise of $0.36 per analyst estimates. Looking ahead, Wall Street consensus projects earnings of $0.30 per share for the upcoming quarter with results expected on July 28, and $2.12 per share for the following quarter anticipated on October 29. The trajectory from negative to positive EPS across sequential quarters suggests an expected recovery path. These estimates reflect analyst expectations for a meaningful earnings inflection as Merck navigates its product cycle transitions and pipeline developments within the competitive pharmaceutical landscape.
Wall Street Analyst Ratings for MRK
Wall Street analyst coverage of Merck & Co. reflects a moderately constructive consensus, per SID consensus data. In October 2026, five major firms reiterated their existing ratings on the stock. Morgan Stanley and JP Morgan both maintained Overweight ratings on October 7 and October 5 respectively, representing the most bullish stances among recent coverage, according to Wall Street analyst reports. Citigroup reiterated its Neutral rating on October 12, while RBC Capital maintained a Sector Perform designation on the same date. Cantor Fitzgerald also held its Neutral rating as of October 8. The distribution shows two of five covering firms at Overweight and three at Neutral or equivalent, indicating a mild positive skew in sentiment. Notably, no analyst downgraded or upgraded their rating in the most recent cycle, suggesting the Street views Merck's current positioning as largely in line with expectations. The absence of any Underweight or Sell ratings among recent coverage is a constructive data point.
